Abstract 1049P
Background
Envafolimab is the world’s first subcutaneously injectable anti-PD-L1 antibody approved by China’s National Medical Products Administration with the injection time of less than 20 seconds. Here, we report the results from a phase Ib/II study of envafolimab plus lenvatinib in patients with selected advanced solid tumors.
Methods
This was an open-label, multi-center trial. 6 patients with advanced solid tumors were enrolled in the phase Ib study for safety evaluation first, and then the phase II was divided into two cohorts. Cohort 1, PD-(L)1 inhibitor therapy resistant advanced non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Cohort 2, treatment naive advanced RCC. The objectives of phase Ib were to assess the safety and determine the recommended phase II dose (RP2D) for envafolimab plus lenvatinib. The primary endpoint of phase II was objective response rate (ORR) per RECIST v1.1.
Results
As cutoff date of March 31 2023, 24 patients were enrolled in phase Ib (n = 6) and the phase II expansion (n = 18). The RP2D was envafolimab 400mg every 4 weeks plus lenvatinib 20 mg/d. In PD-(L)1 resistant NSCLC (n=11), ORR was 27.3 % (95% CI: 6.0% to 61.0%), median duration of response (mDOR) was 4.2 months (95% CI: 3.7 to NE) and median progression-free survival (mPFS) was 8.1 months (95% CI: 1.8 to NE). In treatment naive RCC (n=5), ORR was 80.0% (95% CI: 28.4% to 99.5%), mDOR was NE (95% CI: NE to NE) and mPFS was NE (95% CI, NE to NE). The most common treatment-related adverse events (TRAEs) were proteinuria (75.0%), hypothyroidism (70.8%) and hypertension (62.5%). There were no grade 5 TRAEs and no TRAEs resulted in envafolimab or lenvatinib discontinuation.
Conclusions
Envafolimab in combination with lenvatinib demonstrated a robust preliminary ORR and mPFS in PD-(L)1 resistant NSCLC patients with manageable safety profile. In consistent with the results from other intravenous anti-PD-1 antibody plus Lenvatinib in RCC patients, subcutaneous injection of envafolimab with lenvatinib provided a more convenient dose regimen in this population. Further evaluation of this combination therapy are underway in both populations.
Clinical trial identification
NCT05024214.
Editorial acknowledgement
Legal entity responsible for the study
3D Medicines Inc.
Funding
3D Medicines Inc.
Disclosure
S. Xiao, L. Qin, S. Xu, W. Huang: Financial Interests, Personal, Full or part-time Employment: 3D Medicines Inc.. All other authors have declared no conflicts of interest.
Resources from the same session
1047P - AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Presenter: Ben Tran
Session: Poster session 19
1048P - Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer
Presenter: Nuria Kotecki
Session: Poster session 19
1050P - Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin
Presenter: Joan Russo-Cabrera
Session: Poster session 19
1051P - Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial
Presenter: Stephane Dalle
Session: Poster session 19
1052P - Phase-Ib trial of metformin combined with nivolumab for refractory/recurrent solid tumors
Presenter: Toshio Kubo
Session: Poster session 19
1053P - Tumor-restricted delivery of an immune-therapeutic payload by modified macrophages for the treatment of glioblastoma: The TEM-GBM STUDY (NCT03866109)
Presenter: Fabio Ciceri
Session: Poster session 19
1054P - A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors
Presenter: Songbing Qin
Session: Poster session 19
1055P - Safety and Activity of SmarT cells plus PD-1 blocking antibodies in patients with heavily pretreated solid cancers: An open-label and dose-escalation study
Presenter: Qin Liu
Session: Poster session 19
1056P - Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)
Presenter: Aleix Prat
Session: Poster session 19
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19